AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23743576 — intervention group
Group type: COMPARATOR
Intervention: Nontargeted training with selective-attention demand
Number of subjects: 0
Study 23743576 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted training
Number of subjects: 0
Study 21189381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium/magnesium (1g calcium gluconate plus 1g magnesium sulfate pre‐ and post‐oxaliplatin)
Number of subjects: 102
Study 21189381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 21189381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium/magnesium
Number of subjects: 102
Study 18650514 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 602
Study 18650514 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 602
Study 16537737 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% humidity (n = 46)
Number of subjects: 140
Study 16537737 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% humidity (optimally delivered placebo, n = 46)
Number of subjects: 140
Study 16537737 — intervention group
Group type: COMPARATOR
Intervention: Blow-by humidity (commonly used placebo, n = 48)
Number of subjects: 140
Study 12524639 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperament and Character Inventory (TCI)
Number of subjects: 28
Study 12524639 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 women and their 27 fathers and 29 mothers)
Number of subjects: 28
Study 10940745 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisone for 5 days during upper respiratory infection (URI)
Number of subjects: 36
Study 10940745 — intervention group
Group type: COMPARATOR
Intervention: Alternate‐day prednisone during URI
Number of subjects: 36
Study 9737626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifetroban (250 mg daily)
Number of subjects: 165
Study 9737626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 7920954 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine (0.15 mg/kg bolus followed by 0.15 mg/kg/hour for 12 hours)
Number of subjects: 16
Study 7920954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dosing of ranitidine (1 mg/kg, two doses 6 hours apart)
Number of subjects: 16
Study 7920954 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (continuous infusion and bolus dosing)
Number of subjects: 16
Study 3401271 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl solution
Number of subjects: 12
Study 3401271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulcolax Dragees (2 x 5 mg)
Number of subjects: 12
Study 3401271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulcolax suppository (10 mg)
Number of subjects: 12
Study 29442084 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mouthwash
Number of subjects: 40
Study 29442084 — intervention group
Group type: COMPARATOR
Intervention: Chlorine dioxide mouthwash
Number of subjects: 40
Study 28116300 — intervention group
Group type: EXPERIMENTAL
Intervention: understAID application (experimental group)
Number of subjects: 61
Study 28116300 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 24411804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 20
Study 22412178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy (T&A)
Number of subjects: 60
Study 22412178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy with Pharyngoplasty (T&A + Pharyngoplasty)
Number of subjects: 60
Study 22412178 — intervention group
Group type: COMPARATOR
Intervention: T&A
Number of subjects: 60
Study 22412178 — intervention group
Group type: COMPARATOR
Intervention: T&A + Pharyngoplasty
Number of subjects: 60
Study 20470848 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 40 mg BID for 2 days, titrated up to 80 mg BID thereafter
Number of subjects: 54
Study 20470848 — intervention group
Group type: COMPARATOR
Intervention: abrupt discontinuation of conventional antipsychotics
Number of subjects: 54
Study 20470848 — intervention group
Group type: COMPARATOR
Intervention: fast taper-50% of conventional antipsychotic dosage on days 1 through 7, followed by discontinuation
Number of subjects: 54
Study 20470848 — intervention group
Group type: COMPARATOR
Intervention: slow taper-100% of conventional antipsychotic dosage on days 1 and 2, followed by 50% on days 3 through 7, then discontinuation
Number of subjects: 54
Study 18262432 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (100 mg/die) and atorvastatin (10 mg/die) combined treatment
Number of subjects: 52
Study 16456725 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat fatty fish or fish oil capsules (DART)
Number of subjects: 5147
Study 16456725 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat fatty fish (DART 2)
Number of subjects: 5147
Study 16456725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules (DART 2)
Number of subjects: 5147
Study 16456725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish or fish oil (DART 2)
Number of subjects: 5147
Study 12208717 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI of the optic nerve in ON patients
Number of subjects: 64
Study 12208717 — intervention group
Group type: COMPARATOR
Intervention: MRI of the optic nerve in NAION patients
Number of subjects: 64
Study 9697435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (bereavement intervention)
Number of subjects: 261
Study 9697435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 261
Study 2628313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets (0.5-1.5 mg hourly)
Number of subjects: 120
Study 2628313 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (starting at 2 mU/min, max 64 mU/min)
Number of subjects: 120
Study 2628313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2 tablets
Number of subjects: 120
Study 2628313 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 120
Study 973938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 6
Study 973938 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 6
Study 973938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 973938 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 6
Study 973938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol and Practolol
Number of subjects: 6
Study 30286004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (based on the combination of transverse diameter of cricoid ring and ED-LMB)
Number of subjects: 80
Study 30286004 — intervention group
Group type: COMPARATOR
Intervention: LMB group (based on ED-LMB alone)
Number of subjects: 80
Study 30286004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 80
Study 30286004 — intervention group
Group type: COMPARATOR
Intervention: LMB group
Number of subjects: 80
Study 30468986 — intervention group
Group type: COMPARATOR
Intervention: Community-based cohort (CC) participants
Number of subjects: 800
Study 30468986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based cohort (HC) participants
Number of subjects: 800
Study 30468986 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with alcohol use problems
Number of subjects: 800
Study 30468986 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with past suicide attempts
Number of subjects: 800
Study 30468986 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants on psychiatric treatment
Number of subjects: 800
Study 28966184 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (photography and self-assessment)
Number of subjects: 32
Study 28966184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study 25908682 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 498
Study 25908682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 23414496 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 189
Study 23414496 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 189
Study 21415383 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 4360
Study 21415383 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 4360
Study 21415383 — intervention group
Group type: COMPARATOR
Intervention: glyburide
Number of subjects: 4360
Study 19752472 — intervention group
Group type: COMPARATOR
Intervention: CAMI+ (computer-assisted motivational intervention plus enhanced home visit)
Number of subjects: 235
Study 19752472 — intervention group
Group type: COMPARATOR
Intervention: CAMI-only (computer-assisted motivational intervention only)
Number of subjects: 235
Study 19752472 — intervention group
Group type: COMPARATOR
Intervention: CAMI+
Number of subjects: 235
Study 19752472 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMI-only
Number of subjects: 235
Study 16942833 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine and rehabilitation (group A)
Number of subjects: 112
Study 16942833 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone (group B)
Number of subjects: 112
Study 15067266 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrusion group (n = 21)
Number of subjects: 91
Study 15067266 — intervention group
Group type: EXPERIMENTAL
Intervention: Derotation group (n = 28)
Number of subjects: 91
Study 15067266 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 91
Study 11464356 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic alone (40 mL)
Number of subjects: 40
Study 11464356 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic plus buprenorphine (0.3 mg)
Number of subjects: 40
Study 9713726 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid plus PFC
Number of subjects: 10
Study 9713726 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid alone
Number of subjects: 10
Study 7809537 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (6 mg/kg/day for 120 days)
Number of subjects: 202
Study 7809537 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (8.5 mg/kg/day for 60 days)
Number of subjects: 202
Study 7809537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 60 days)
Number of subjects: 202
Study 3422261 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG) for 6 cycles
Number of subjects: 187
Study 3422261 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG)
Number of subjects: 187
Study 358140 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroergotoxine
Number of subjects: 34
Study 30797045 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanitarian intervention targeting stress-alleviation
Number of subjects: 817
Study 30794976 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0
Study 30794976 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Number of subjects: 0
Study 28007348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihormonal bionic pancreas
Number of subjects: 43
Study 28007348 — intervention group
Group type: COMPARATOR
Intervention: Usual care (conventional or sensor-augmented insulin pump therapy)
Number of subjects: 43
Study 24938396 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 16
Study 24938396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP injections)
Number of subjects: 16
Study 23456672 — intervention group
Group type: EXPERIMENTAL
Intervention: IM clodronate 100 mg twice weekly (Group B)
Number of subjects: 60
Study 23456672 — intervention group
Group type: COMPARATOR
Intervention: IM clodronate 100 mg once weekly (Group A)
Number of subjects: 60
Study 22331940 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 493
Study 22331940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide plus rituximab (FCR)
Number of subjects: 493
Study 22331940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MRD levels
Number of subjects: 493
Study 22331940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate MRD levels
Number of subjects: 493
Study 22331940 — intervention group
Group type: EXPERIMENTAL
Intervention: High MRD levels
Number of subjects: 493
Study 20163263 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium patch
Number of subjects: 120
Study 20163263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17367356 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency (CRI)
Number of subjects: 336
Study 17367356 — intervention group
Group type: COMPARATOR
Intervention: Non-chronic renal insufficiency (non-CRI)
Number of subjects: 336
Study 16301721 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of water ingestion before ultrasonographic examination (Group A)
Number of subjects: 150
Study 16301721 — intervention group
Group type: COMPARATOR
Intervention: No water ingestion at least 4 hours before the procedure (Group B)
Number of subjects: 150
Study 16301721 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of water ingestion (Group A)
Number of subjects: 150
Study 16301721 — intervention group
Group type: COMPARATOR
Intervention: No water ingestion (Group B)
Number of subjects: 150
Study 16301721 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 150
Study 12070447 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-angiography
Number of subjects: 196
Study 9793190 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog plus oral contraceptive (OC) therapy
Number of subjects: 30
Study 9793190 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC) therapy alone
Number of subjects: 30
Study 7657122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, 20 mg/day per os (group A)
Number of subjects: 120
Study 7657122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 120
Study 7657122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (group A)
Number of subjects: 120
Study 2568711 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-agonist
Number of subjects: 44
Study 2568711 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 2568711 — intervention group
Group type: EXPERIMENTAL
Intervention: pharmacological treatment
Number of subjects: 44
Study 364917 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (1 mg in viscous gel)
Number of subjects: 61
Study 31926951 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening (14‐20 weeks)
Number of subjects: 962
Study 31926951 — intervention group
Group type: COMPARATOR
Intervention: Routine screening (24‐28 weeks)
Number of subjects: 962
Study 31279865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloysia polystachya powdered leaves (300 mg, twice a day)
Number of subjects: 54
Study 31279865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 54
Study 25363466 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week DAFNE course
Number of subjects: 213
Study 25363466 — intervention group
Group type: COMPARATOR
Intervention: 5-week DAFNE course
Number of subjects: 213
Study 25363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline HbA1c ≥ 58 mmol/mol (≥ 7.5%)
Number of subjects: 213
Study 25363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both course formats
Number of subjects: 213
Study 23942532 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-group-derived benchmarks (PGD-training)
Number of subjects: 68
Study 23942532 — intervention group
Group type: COMPARATOR
Intervention: Self-controlled basic VR training (SC-training)
Number of subjects: 68
Study 21991734 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC placement with ultrasound guidance
Number of subjects: 325
Study 21991734 — intervention group
Group type: COMPARATOR
Intervention: CVC placement without ultrasound guidance
Number of subjects: 325
Study 21991734 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced ultrasound practitioners
Number of subjects: 325
Study 21991734 — intervention group
Group type: COMPARATOR
Intervention: Non-experienced ultrasound practitioners
Number of subjects: 325
Study 19627288 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 1520
Study 19627288 — intervention group
Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 1520
Study 16460294 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg for infants under 12 months, 40 mg for older children)
Number of subjects: 187
Study 16460294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (50,000 IU for infants under 12 months, 100,000 IU for older children)
Number of subjects: 187
Study 16460294 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + Vitamin A supplementation
Number of subjects: 187
Study 16460294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no supplementation)
Number of subjects: 187
Study 15148064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 132
Study 15148064 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 132
Study 15148064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (in persons with diabetes)
Number of subjects: 132
Study 10648454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (4 g daily for 18 months)
Number of subjects: 318
Study 10648454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 10648454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (4 g daily for 18 months) in isolated small bowel disease subgroup
Number of subjects: 318
Study 10648454 — intervention group
Group type: COMPARATOR
Intervention: Placebo in isolated small bowel disease subgroup
Number of subjects: 318
Study 9308977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pyridoxine (30 or 50 mg/kg/day) by intravenous infusion
Number of subjects: 90
Study 9308977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pyridoxine)
Number of subjects: 90
Study 8315942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis with new CU membrane
Number of subjects: 8
Study 3548301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem, 120 to 180 mg twice daily
Number of subjects: 207
Study 3548301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 25 to 50 mg twice daily
Number of subjects: 207
Study 3548301 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg/day
Number of subjects: 207
Study 30342255 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPSHOT intervention (9-month program including four home visits, 14 kid groups, and five parent groups)
Number of subjects: 132
Study 30342255 — intervention group
Group type: COMPARATOR
Intervention: Newsletter program (monthly mailings and family-focused healthy lifestyle information)
Number of subjects: 132
Study 30342255 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPSHOT intervention
Number of subjects: 132
Study 30342255 — intervention group
Group type: COMPARATOR
Intervention: Newsletter program
Number of subjects: 132
Study 26464170 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary HSCT (group A; N=166 patients)
Number of subjects: 669
Study 26464170 — intervention group
Group type: COMPARATOR
Intervention: Best available drug treatment (group B; N=261 patients)
Number of subjects: 669
Study 24951633 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability, Current issues and Anticipation training programme
Number of subjects: 145
Study 24951633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 145
Study 22197071 — intervention group
Group type: COMPARATOR
Intervention: C1-inhibitor concentrate (C1-INH)
Number of subjects: 13
Study 22197071 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-inhibitor concentrate (C1-INH-NF)
Number of subjects: 13
Study 21153932 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music through headphones for one hour after surgery)
Number of subjects: 70
Study 21153932 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 70
Study 21153932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 70
Study 18764771 — intervention group
Group type: EXPERIMENTAL
Intervention: ETR (400 mg or 800 mg twice daily)
Number of subjects: 240
Study 18764771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 18764771 — intervention group
Group type: EXPERIMENTAL
Intervention: ETR (800 mg or 1200 mg twice daily)
Number of subjects: 240
Study 18764771 — intervention group
Group type: EXPERIMENTAL
Intervention: ETR
Number of subjects: 240
Study 16269047 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced immunosuppression with basiliximab
Number of subjects: 59
Study 16269047 — intervention group
Group type: COMPARATOR
Intervention: Control group with triple-therapy (azathioprine, methylprednisolone, cyclosporine)
Number of subjects: 59
Study 12006915 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (surgical intervention)
Number of subjects: 789
Study 12006915 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 789
Study 12006915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (partial ileal bypass)
Number of subjects: 789
Study 10188004 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 16
Study 10188004 — intervention group
Group type: COMPARATOR
Intervention: TENS in early stage AD
Number of subjects: 16